Slide 1: Third Quarter FY 2012 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) Third Quarter FY 2012 Conference Call and Webinar July 12, 2012
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 3Q12 Highlights
• 3Q12 compared to 3Q11: – 19 th consecutive profitable quarter – Sales up 5.0% to Record 3 rd Quarter$2.77 MM from $2.64 MM – Gross profit up 6.8% to $2.33 million from $2.19 million – SG&A up 14.5% to $0.89 million from $0.78 million • Increased health/dental, liability, and Worker’s Compensation
Slide 4: 9moFY12 Highlights
• 9moFY12 compared to 9moFY11: – Sales up 6.8% to Record 9-Monthsat $7.808 MM from $7.312 MM – Gross profit up 9.1% to $6.622 million from $6.069 million – SG&A up 15.1% to $2.548 million from $2.213 million • Legal fees for attempted acquisition of Entelos’ assets in bankruptcy court • Final paymen
Slide 5: Income Statement 3QFY12 vs 3QFY11
Income Statement 3QFY12 vs3QFY11 ($ millions) 3Q12 3Q11 (pro forma) Net sales 2.772 2.640 Gross profit 2.334 2.186 Gross profit margin 84.2% 82.8% SG&A 0.891 0.778 R&D 0.228 0.100 Total operating expenses 1.119 0.878 Income from continuing operations 0.869 1.044 Other income 0.077 0.057 Income from
Slide 6: Income Statement 9moFY12 vs 9moFY11
Income Statement 9moFY12 vs9moFY11 ($ millions) 3Q12 3Q11 (pro forma) Net sales 7.808 7.311 Gross profit 6.622 6.068 Gross profit margin 84.8% 83.0% SG&A 2.547 2.213* R&D 0.745 0.428* Total operating expenses 3.292 2.641 Income from continuing operations 2.463 2.487 Other income 0.285 0.110 Income f
Slide 7: Revenues by Fiscal Year
$3.2 $5.7 $6.1 $6.3 $7.6 $8.7 $7.8 2006 2007 2008 2009 2010 2011 2012 $ M i l l i o n s 2006 2007 2008 2009 2010 2011 2012 9 mo only Revenues by Fiscal Year (pro forma prior to 2012)
Slide 8: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $1.4 $1.6 $2.0 $1.1 $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $0 $1 $2 $3 Q1 Q2 Q3 Q4 2008 2009 2010 2011 2012 $2.77 $2.2 $2.79
Slide 9: Gross Profit by Fiscal Year
$5.2 $6.4 $7.2 $6.6 2009 2010 2011 2012 $ M i l l i o n s 2009 2010 2011 2012 9 mo only Gross Profit by Fiscal Year (pro forma prior to 2012)
Slide 10: Gross Profit by Fiscal Quarter
Gross Profit by Fiscal Quarter (pro forma prior to 2012) $1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 Q1 Q2 Q3 Q4 2009 2010 2011 2012
Slide 11: EBITDA by Fiscal Year
$2.4 $3.6 $4.2 $3.8 2009 2010 2011 2012 $ M i l l i o n s 2009 2010 2011 2012 9 mo only EBITDA by Fiscal Year (pro forma prior to 2012)
Slide 12: EBITDA by Fiscal Quarter
EBITDA by FiscalQuarter $0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.27 $1.11 $1.33 $1.40 Q1 Q2 Q3 Q4 2009 2010 2011 2012
Slide 13: Net Income by Fiscal Year
$0.4 $1.3 $1.7 $2.0 $2.2 $2.6 9 mo only $2.7 $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 $3.0 2006 2007 2008 2009 2010 2011 2012 $ M i l l i o n s 2006 2007 2008 2009 2010 2011 2012 Net Income by Fiscal Year (pro forma prior to 2012)
Slide 14: Net Income by Quarter
Net Income by Quarter (pro forma prior to 2012) $0.39 $0.49 $0.58 $0.25 $0.33 $0.47 $0.53 $0.17 $0.44 $0.85 $0.74 $0.21 $0.56 $0.91 $1.05 $0.17 $0.76 $0.84 $0.87 Q1 Q2 Q3 Q4 2008 2009 2010 2011 2012
Slide 15: Selected Balance Sheet Items
Selected Balance Sheet Items ($ millions) May 31, 2012 August 31, 2011 Cash and cash equivalents $12.889 $10.181 Cash per share 0.789 0.537 Total current assets 15.777 13.275 Total assets 18.412 15.867 Total current liabilities 1.935 1.141 Total liabilities 2.809 1.830 Current ratio 8.2 11.6 Shareho
Slide 16: Simulations Plus Products & Services
N H O OH O CH 3 CH 3 CH 3 Discovery Preclinical Clinical MedChem Studio™ MedChem Designer™ GastroPlus™ DDDPlus™ ADMET Predictor™ Simulations Plus Products & Services Consulting Services & Collaborations MembranePlus™
Slide 17: Recent Enhancements
• Simulations Plus continues to increase its technological advantage Recent Enhancements • Version 8.0 released May 2012 • Expanded drug-drug interaction to include transporters and induction • Expanded PDPlus™ pharmacodynamics modeling module • Expanded ocular delivery model • Expanded nasal/pulmon
Slide 18: Marketing and Sales Program
Marketing and Sales Program • Added Cheminformatics salesperson July 2012 to increase sales of ADMET Design Suite™ (MedChem Studio™, MedChem Designer™, and ADMET Predictor™) • Conferences/Scientific Meetings continue to be primary source of leads • During Q3 we did 17 meetings in the U.S., Europe, a
Slide 19: FDA Food Safety Research Collaboration
FDA Food Safety Research Collaboration • Entered into a 5-year renewable Research Collaboration with Center for Food Safety and Applied Nutrition (CFSAN) to provide model-building capabilities for a large number (>70,000) of substances that can be in foods as additives or contaminants • FDA has data
Slide 20: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project • A new molecule that has never existed before is called a new chemical entity (NCE). Drug companies try to design and patent NCEs to treat diseases or to affect lifestyles. • Getting to an approvable drug molecule usually involves making and testing a large number
Slide 21: Summary
Summary • For 3QFY12 and 9moFY12: - Financial performance continues our profitable trend - Higher SG&A was expected after the sale of Words+, and is being felt - Sale of Words+ has simplified and focused the business - margins increased about 10%, reporting and auditing much simpler • Continuing to
Slide 22: Simulations Plus, Inc.
simulationsplus, inc. cs